The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pharmacokinetics and pharmacodynamics of the GCN2 activator HC-7366 in a phase 1a study in patients with advanced solid tumors.
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); Curio Science (Inst); CytomX Therapeutics (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Pfizer (Inst); Takeda (Inst)
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Fog Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Leap Therapeutics (Inst); Neogene (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Seagen (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Takeda (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Kanwal Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
 
Jordan Berlin
Consulting or Advisory Role - Agenus; ALX Oncology; amplia; Astellas Pharma; BeiGene; Bristol-Myers Squibb/Celgene; epsilon; insmed; ipsen; Mekanistic Therapeutics; Merck KGaA; Regeneron; Taiho Oncology
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Bristol-Myers Squibb/Celgene (Inst); clasp (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); I-MAB (Inst); Incendia Pharmaceuticals AB (Inst); Incyte (Inst); Lilly (Inst); Nested Therapeutics (Inst); ribosciences (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Ipsen; Merck KGaA
Other Relationship - AstraZeneca; Boehringer Ingelheim; novocure
 
Daniel Morgensztern
Consulting or Advisory Role - Abbvie; Bayer; Bristol-Myers Squibb/Medarex; Johnson & Johnson/Janssen; Lilly Medical; Mirati Therapeutics; Natera; Tubulis GmbH
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genprex (Inst); Hybercell (Inst); ImmunityBio (Inst); Lilly (Inst); Merck (Inst); NeoImmuneTech (Inst); Nextcure (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst); Tubulis GmbH (Inst)
Patents, Royalties, Other Intellectual Property - Genprex
 
Sunnie Kim
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; BeiGene; Bristol Myers Squibb; Coherus Biosciences; Daiichi Sankyo/Lilly; Gilead Sciences; I-Mab; Jazz Pharmaceuticals; Merck
Research Funding - Merck
 
Philip Gold
No Relationships to Disclose
 
Peter Vu
No Relationships to Disclose
 
Jeremy Drees
Employment - HiberCell
Stock and Other Ownership Interests - HiberCell
Patents, Royalties, Other Intellectual Property - Authorship on pending patents related to HiberCell intellectual property. (Inst)
Travel, Accommodations, Expenses - HiberCell
 
Eric Lightcap
Employment - HiberCell
Stock and Other Ownership Interests - HiberCell
Research Funding - HiberCell
Patents, Royalties, Other Intellectual Property - HiberCell (Inst)
 
Ben Harrison
Employment - HealthPartners (I); HiberCell
Stock and Other Ownership Interests - HealthPartners (I); HiberCell
Patents, Royalties, Other Intellectual Property - Biothera
 
Weiyu Zhang
Employment - HiberCell
Stock and Other Ownership Interests - HiberCell
Research Funding - HiberCell
 
Anissa Chan
Employment - HiberCell
 
Crissy Dudgeon
Employment - HiberCell
 
Ashley LaCayo
Employment - Hibercell
Stock and Other Ownership Interests - Hibercell
 
Dhamina Karim
Employment - HiberCell
 
Michele Gargano
Employment - HiberCell
Stock and Other Ownership Interests - HiberCell
 
Nandita Bose
Employment - HiberCell
Leadership - HiberCell
Stock and Other Ownership Interests - HiberCell